Novartis stock slips as Jefferies and UBS stay neutral after Hybrozyme deal
Published on 09/04/2026 at 18:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Novartis (ISIN CH0012005267) stock traded lower on the Swiss Exchange on September 4, 2026, with the share recently quoted around 129.94 CHF after intraday losses of about 1.1 percent according to market data compiled by finanzen.ch.
Analysts keep a neutral stance
According to an analysis reported by MarketScreener on September 4, 2026, Jefferies has reaffirmed its Neutral rating on Novartis, leaving the price target unchanged at 110 CHF.
The same MarketScreener overview shows that Novartis closed its latest US ADR session at 162.64 USD, while the average analyst price target stands at 154.38 USD, implying about 5.08 percent downside versus that closing price.
DACH analyst view with Remibrutinib focus
A separate assessment on September 4, 2026 from finanzen.at citing UBS notes that UBS has maintained a Neutral recommendation on Novartis with a price target of 116 CHF, based on recent Remibrutinib trial results in relapsing multiple sclerosis.
According to this UBS-linked analysis, the current Novartis share price used in the rating context is around 129.82 CHF, which is about 10.65 percent above the 116 CHF target, underscoring that the stock already trades at a premium to that DACH-house valuation.
More facts and background on Novartis
Investors can review additional data, filings and news on Novartis to complement this stock snapshot.
Hybrozyme licensing deal boosts long term narrative
On September 3, 2026, Novartis was highlighted in a detailed analysis by 247WallSt, which described a licensing arrangement with Alteogen for the Hybrozyme drug delivery platform.
The article cites that, based on the option and license structure, Alteogen could receive up to about 3.223 billion USD in milestone payments if Novartis exercises all options and successfully develops and commercializes the subcutaneous formulations under the deal.
In the same coverage, Novartis ADRs are described as trading at around 162.46 USD with an estimated market capitalization of roughly 308.79 billion USD, and the one year share price gain is quantified at 32.21 percent, illustrating the strong performance leading into the Hybrozyme agreement.
Strategic and operational shifts in Basel
Beyond capital markets, Novartis is also adjusting its Swiss footprint. According to a report on Yahoo Finance published on September 4, 2026, the company plans to relocate certain laboratory activities and end small scale biologics production at its Kleinbasel site.
Novartis could cut around 130 jobs in Switzerland as these laboratories supporting biological cell banks, analytical testing and technical development are moved to the main Basel campus, with small scale biologics production at Kleinbasel expected to end by the end of 2027.
Product focus: Kisqali and oncology portfolio
The 247WallSt analysis emphasizes that Novartis is leaning on growth drivers such as the breast cancer drug Kisqali alongside Pluvicto and Scemblix to offset declines in legacy brands like Entresto.
According to that article, consensus forecasts point toward 2027 earnings per share of about 9.81 USD, and the stock trades at roughly 23 times trailing earnings and around 17 times forward earnings in the current valuation framework.
Stock in focus on the Swiss Exchange
Market data from finanzen.ch show that on September 4, 2026, at 16:28, Novartis shares on SIX Swiss Exchange traded at 129.94 CHF, down about 1.1 percent on the day.
During the same session, the intraday low was reported at 129.40 CHF, while the opening price stood at 130.66 CHF, placing the stock modestly weaker in the context of the Swiss Market Index, which was quoted around 14,399 points.
Novartis stock at a glance
- Company: Novartis AG
- ISIN: CH0012005267
- Ticker: NOVN
- Trading venue: SIX Swiss Exchange
- Price (as of September 4, 2026, 16:28): 129.94 CHF
- Market capitalization: 308.79 billion USD (as of September 3, 2026)
- Sector / Industry: Pharmaceuticals / Biotechnology
- Index membership: SMI
